STAT Plus: Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

Unlike most biotech startups, Enlight Biosciences was never expected to make any drugs.

Instead, the company intended to develop a whole host of promising, biotech-adjacent ideas. One would help connect clinical researchers with interested companies. Another would figure out how to use ultrasounds to diagnose a common liver disease. Yet another would transform a class of injectable drugs into pills.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Enlight Biosciences was going to ‘transform pharma R&D.’ What happened? »